HUE054347T2 - MK2 inhibitorok és azok alkalmazásai - Google Patents

MK2 inhibitorok és azok alkalmazásai

Info

Publication number
HUE054347T2
HUE054347T2 HUE15842903A HUE15842903A HUE054347T2 HU E054347 T2 HUE054347 T2 HU E054347T2 HU E15842903 A HUE15842903 A HU E15842903A HU E15842903 A HUE15842903 A HU E15842903A HU E054347 T2 HUE054347 T2 HU E054347T2
Authority
HU
Hungary
Prior art keywords
inhibitors
Prior art date
Application number
HUE15842903A
Other languages
English (en)
Inventor
Matthew David Alexander
Claudio Chuaqui
John Malona
Joseph John Mcdonald
Yike Ni
Deqiang Niu
Russell C Petter
Juswinder Singh
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of HUE054347T2 publication Critical patent/HUE054347T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
HUE15842903A 2014-09-17 2015-09-16 MK2 inhibitorok és azok alkalmazásai HUE054347T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
HUE054347T2 true HUE054347T2 (hu) 2021-08-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15842903A HUE054347T2 (hu) 2014-09-17 2015-09-16 MK2 inhibitorok és azok alkalmazásai

Country Status (30)

Country Link
US (5) US9458175B2 (hu)
EP (2) EP3912981A1 (hu)
JP (3) JP6556225B2 (hu)
KR (1) KR102457848B1 (hu)
CN (1) CN106998692B (hu)
AU (1) AU2015317741B2 (hu)
BR (1) BR112017005266B1 (hu)
CA (1) CA2961607C (hu)
CL (1) CL2017000576A1 (hu)
CO (1) CO2017003279A2 (hu)
CY (1) CY1124215T1 (hu)
DK (1) DK3193611T3 (hu)
EA (1) EA037299B1 (hu)
EC (1) ECSP17023281A (hu)
ES (1) ES2874561T3 (hu)
HR (1) HRP20210529T1 (hu)
HU (1) HUE054347T2 (hu)
IL (1) IL251051B (hu)
LT (1) LT3193611T (hu)
MA (1) MA40534B1 (hu)
MX (2) MX2017003359A (hu)
NZ (1) NZ730603A (hu)
PL (1) PL3193611T3 (hu)
PT (1) PT3193611T (hu)
RS (1) RS62017B1 (hu)
SA (1) SA517381115B1 (hu)
SG (2) SG11201701861RA (hu)
SI (1) SI3193611T1 (hu)
TW (1) TWI744217B (hu)
WO (1) WO2016044463A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
SG11201701861RA (en) 2014-09-17 2017-04-27 Celgene Car Llc Mk2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
EP3596086A4 (en) * 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREFORE
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
EP3969456A4 (en) * 2019-05-17 2023-01-25 Celgene CAR LLC METHODS OF TREATMENT OF MK2-MEDIATED DISEASE
EP4103186A4 (en) * 2020-02-14 2024-03-06 Salk Inst For Biological Studi MONO- AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006514043A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
AR052476A1 (es) 2005-02-04 2007-03-21 Senomyx Inc Compuestos que comprenden restos heteroarilo conectados y su uso como modificadores novedosos del sabor umami, estmuladores e intensificadores del gusto para composiciones comestibles
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0814426A2 (pt) 2007-07-16 2015-01-06 Novartis Ag Compostos heterocíclicos úteis como inibidores de mk2
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102083800A (zh) 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
AU2013319774A1 (en) * 2012-09-24 2015-05-14 Claremont SPEEDE Mobile sender controlled data access and data deletion method and system
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
SG11201701861RA (en) 2014-09-17 2017-04-27 Celgene Car Llc Mk2 inhibitors and uses thereof
SG11201705559RA (en) 2015-01-08 2017-08-30 Moerae Matrix Inc Formulation of mk2 inhibitor peptides
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREFORE
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
EP3969456A4 (en) 2019-05-17 2023-01-25 Celgene CAR LLC METHODS OF TREATMENT OF MK2-MEDIATED DISEASE
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
EA037299B1 (ru) 2021-03-05
ECSP17023281A (es) 2017-06-30
US10577380B2 (en) 2020-03-03
EP3193611B1 (en) 2021-03-24
WO2016044463A2 (en) 2016-03-24
MX2017003359A (es) 2017-11-22
AU2015317741B2 (en) 2020-01-16
DK3193611T3 (da) 2021-05-10
SG11201701861RA (en) 2017-04-27
EP3193611A4 (en) 2018-02-28
SG10201902326XA (en) 2019-04-29
EP3912981A1 (en) 2021-11-24
US20160075720A1 (en) 2016-03-17
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US9458175B2 (en) 2016-10-04
US20170114073A1 (en) 2017-04-27
US9790235B2 (en) 2017-10-17
MA40534B1 (fr) 2021-04-30
BR112017005266A2 (pt) 2017-12-12
KR20170063734A (ko) 2017-06-08
NZ730603A (en) 2024-02-23
CN106998692A (zh) 2017-08-01
JP2022078315A (ja) 2022-05-24
TWI744217B (zh) 2021-11-01
US20210053984A1 (en) 2021-02-25
JP2017529367A (ja) 2017-10-05
EA201790380A1 (ru) 2017-08-31
JP2019194236A (ja) 2019-11-07
US10253040B1 (en) 2019-04-09
EP3193611A2 (en) 2017-07-26
TW201617351A (zh) 2016-05-16
SI3193611T1 (sl) 2021-08-31
BR112017005266B1 (pt) 2022-11-01
CA2961607C (en) 2023-03-28
US11584757B2 (en) 2023-02-21
LT3193611T (lt) 2021-08-25
AU2015317741A1 (en) 2017-04-20
IL251051A0 (en) 2017-04-30
IL251051B (en) 2019-11-28
US20190375762A1 (en) 2019-12-12
MX2020005213A (es) 2020-08-20
SA517381115B1 (ar) 2021-03-09
WO2016044463A3 (en) 2016-09-01
CA2961607A1 (en) 2016-03-24
PT3193611T (pt) 2021-05-28
PL3193611T3 (pl) 2021-10-04
MA40534A (fr) 2016-03-24
CN106998692B (zh) 2020-09-08
JP7375072B2 (ja) 2023-11-07
KR102457848B1 (ko) 2022-10-25
CO2017003279A2 (es) 2017-09-29
CY1124215T1 (el) 2022-05-27
CL2017000576A1 (es) 2017-12-01
RS62017B1 (sr) 2021-07-30
JP6556225B2 (ja) 2019-08-07

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251051B (en) mk2 inhibitors and their uses
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
GB201411197D0 (en) Composition and use thereof
GB201605126D0 (en) Inhibitors and their uses
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HUE060941T2 (hu) Halogénolefin-bázisú készítmény és alkalmazása
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
IL251077B (en) Integrin inhibitors and their use
HK1250926A1 (zh) 抑制劑及其應用
IL251078B (en) Integrin inhibitors and their use
GB201411196D0 (en) Composition and use thereof
GB201408091D0 (en) Methods and uses
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB201418154D0 (en) Inhibitors
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses